Nobumoto Tomioka

The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC)

Nobumoto Tomioka, Manabu Azuma, Mayuko Ikarashi et al. · Breast Cancer · 2017 · 105 citations

Breast Oncology, Cancer Immunosurveillance, Death Ligand 1 +11

Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature

Nobumoto Tomioka, Shinya Oba, Miki Ohira et al. · Oncogene · 2007 · 81 citations

Glioma, Medicine, Pathology +10

Identification and characterization of a 500-kb homozygously deleted region at 1p36.2-p36.3 in a neuroblastoma cell line

Miki Ohira, Hajime Kageyama, Motohiro Mihara et al. · Oncogene · 2000 · 77 citations

Neuro-oncology, Neuroblastoma Cell Line, Developmental Biology +7

Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)

Jun Masuda, Hitomi Sakai, Junji Tsurutani et al. · Journal for ImmunoTherapy of Cancer · 2023 · 59 citations · Full text

Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer

Hiroko Yamashita, Akiko Ogiya, Tadahiko Shien et al. · Breast Cancer · 2015 · 45 citations

Breast Oncology, Medicine, Clinicopathological Factors +8